Navigation Links
MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
Date:11/25/2008

VALENCIA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008 at 2:30 PM (EST) at the New York Palace Hotel in New York City.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at https://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
2. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
3. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
4. MannKind to Present at the UBS Global Life Sciences Conference
5. MannKind Corporation Reports Second Quarter Financial Results
6. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
7. MannKind to Present at Upcoming Conferences
8. MannKind Corporation Reports First Quarter Financial Results
9. MannKind to Present at the Morgan Stanley Healthcare Conference
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Web addicts, take heart: A public-private effort is moving ... , AOL-SkyCable has been chosen to enter negotiations ... for the general public. The "Wireless Wisconsin" service would ... Madison and the Dane County Regional Airport. The project ...
... Information-technology businesses are taking apart their processes ... 2005 CEO-CIO Symposium on Wednesday just around the ... offered their opinions on how the state and its ... year progresses. , Restructuring and rebuilding ,According to ...
... Johnson Controls Inc. has completed ... a French company, Valeo. Valeo is based in ... million) for the business, headquartered in Pontoise, France, ... engines. Johnson Controls bought the division from another ...
Cached Biology Technology:Madison wi-fi plans move ahead 2Restructuring is a watchword for IT in 2005 2Restructuring is a watchword for IT in 2005 3
(Date:10/22/2014)... 20, 2014 The Nano-Bio Manufacturing Consortium (NBMC), ... Research Laboratory (AFRL), has chosen a project proposed by ... University of Arizona College of Medicine – ... project,s goal is to assess different sweat collection methods ... of sweat under a variety of human-body conditions, the ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... SAN FRANCISCO An increasing number of obese adolescents, ... case study presented Sunday, Oct. 3, at the American ... San Francisco, highlights the possible link between gastric bypass ... neural tube defects, which can lead to varying degrees ...
... of private health insurance and its consequent lack of ... with uterine cancer and may partly explain the mortality ... data presented at the Third AACR Conference on The ... twice as likely to die within four years compared ...
... breast cancer that lacked estrogen and progesterone receptors and did ... those with other types of invasive breast cancer, according to ... Science of Cancer Health Disparities, held Sept. 30 Oct. ... in Puerto Rico, following U.S. trends, it is important to ...
Cached Biology News:Loss of nutrients following gastric bypass surgery in adolescent girls 2Lack of private health insurance impacted cancer survival 2Decreased survival for Puerto Rican women with 'triple-negative' breast cancer subtype 2
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: